-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 15, 2022, Rico Biotech held a head-to-head data interpretation meeting
of the new adjuvant new crown pneumonia vaccine ReCOV and Pfizer mRNA vaccine.
While actively promoting innovative vaccine pipelines, Rico Biotech has also established a self-developed new adjuvant technology platform to become the "core"
of vaccines.
Rico Biotech is also one of the
few companies that can develop multiple novel adjuvants (AS01, AS03, AS04, CpG018 and MF59) that are approved by the FDA.
Rico Bio's ReCOV adopts a trimeric protein structure, including NTD and RBD, covering the main advantages of neutralizing epitopes, and finally selecting the optimal antigen from the 22 antigen
proteins designed under the structure-based immunogen design concept guided by neutralizing antibodies.
In the rhesus monkey model, 7 new adjuvants and traditional aluminum adjuvants were compared, and finally BFA03 new adjuvants were selected, which had a good safety record, the fastest production rate and the highest
titer of neutralizing antibodies.
ReCOV has conducted 10 clinical studies
at home and abroad.
In terms of safety, ReCOV has shown good tolerability and safety
in both Caucasians and Asians.
ReCOV as a primary immunization (New Zealand Phase I and Philippine Phase II) induces a high level of sustained immune response with neutralizing antibody titers no lower than those reported in mRNA vaccines
.
ReCOV-induced humoral and cellular immune responses can last for at least 6 months
.
In the Phase II booster study in the UAE, ReCOV was significantly more effective than inactivated vaccines
against the neutralizing antibody levels of both the prototype strain and Omicron BA.
2.
In cross-sectional comparison, ReCOV, as a heterologous booster-induced neutralizing antibody, has obvious advantages
over other protein seedlings and Pfizer's mRNA vaccines.
Head-to-head comparison of ReCOV versus Pfizer mRNA vaccine
Head-to-head comparison of ReCOV versus Pfizer mRNA vaccineOf particular focus is Rico's head-to-head booster phase II clinical trial with Pfizer's mRNA vaccine in the Philippines, where 600 subjects completed 2 doses of inactivated vaccination and were randomized to ReCOV vaccine and Pfizer's mRNA vaccine
.
The results showed that the level of neutralizing antibody induced by ReCOV was 25.
1 times higher than baseline for the neutralizing antibody level of the prototype strain, which was significantly higher than that of the Pfizer mRNA vaccine and 1.
4 times
higher than that of the Pfizer mRNA vaccine.
Whether it is the adult subgroup or the elderly subgroup, ReCOV-induced prototype strain neutralizing antibodies are significantly higher than those of Pfizer mRNA vaccine
.
Especially for the elderly, this advantage is even more significant
.
The interval between the last dose of inactivated vaccination is also an important factor, and ReCOV boosters performed more than 6 months apart can induce higher levels of neutralizing antibodies
against the prototype strain.
For the neutralizing antibody levels of Omicron BA.
2 and BA.
5, the neutralizing antibody levels induced by ReCOV were 21.
8 times and 22.
5 times higher than the baseline, respectively, which was also significantly higher than that of the Pfizer mRNA vaccine
.
Whether it is the adult subgroup or the elderly subgroup, ReCOV-induced prototype strain neutralizing antibodies are significantly higher than those of Pfizer mRNA vaccine
.
The interval between the last dose of inactivated vaccination is also an important factor, and ReCOV booster immunization more than 6 months apart can induce higher levels of neutralizing antibodies
against the Omicron BA.
2 and BA.
5 variants.
In different spaced populations, ReCOV can induce higher Omicron BA.
2 and BA.
5 neutralizing antibodies
than Pfizer mRNA vaccines.
For RBD-specific binding antibodies, ReCOV is also significantly higher than that of Pfizer mRNA vaccines, 1.
4 times
higher.
ReCOV is more difficult to escape, and its induction of neutralizing antibodies against the Omicron variant is significantly lower than that of other new crown vaccines, including inactivated vaccines, other protein seedlings, and Pfizer mRNA vaccines
.
Rico Biotech is well prepared
for the commercial production of ReCOV.
summary
summaryRico Bio's ReCOV effectiveness has significant advantages, and both the prototype strain and the Omicron variant can induce durable neutralizing antibodies, and the titer is significantly higher than that of the Pfizer mRNA vaccine.
At the same time, ReCOV has good safety characteristics, and there is no difference
between adults and the elderly.
On December 13, the Comprehensive Group of the Joint Prevention and Control Mechanism of the State Council in Response to the Novel Coronavirus Pneumonia Epidemic released the implementation plan for the second dose of booster immunization, of which protein vaccines are the core
.
In the current situation of shifting epidemic prevention and control measures and rapid outbreaks of large-scale epidemics in many places, ReCOV is expected to provide better protection
for Singaporeans, especially the elderly.
